Mar 30, 2017

VivaGel BV phase 3 trials for prevention of BV completed

VivaGel BV phase 3 trials for prevention of BV completed

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

 This contains certain forward-looking statements.